Subscribe
Logo smallSearch
banner

The safety and comfort of the treatment of MS patients is improved

MedExpress Team

Medexpress

Published May 13, 2022 12:34

The safety and comfort of the treatment of MS patients is improved - Header image
The Lancet Neurology published the results of the phase 3b NOVA study assessing the effectiveness of natalizumab administered every six weeks in the treatment of patients with relapsing-remitting multiple sclerosis.

The results of the NOVA study show that natalizumab given intravenously every six weeks provides a high level of effectiveness in controlling MS activity in patients who switched from the every four weeks dosing regimen. The 6-week schedule has already been approved by the EMA.

- The NOVA study is the first prospective study to evaluate the natalizumab dosing regimen every six weeks in patients with relapsing-remitting MS. It i...

Content locked

To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].

If you already have an account, please log in

Topics

SM / natalizumab

Szukaj nowych pracowników

Dodaj ogłoszenie już za 4 zł dziennie*.

* 4 zł netto dziennie. Minimalny okres ekspozycji ogłoszenia to 30 dni.